This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

54/100

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Abstract Background Blood based biomarkers of Alzheimer´s disease (AD) that exhibit a high degree of change over time and are associated with deterioration in cognitive performance and atrophy could be useful in clinical trials to monitor treatment responses. Result In the whole cohort, p ‐tau217, NfL, GFAP and p ‐tau181 were significantly increased over time showing more accelerated increase in Aβ+ than Aβ‐ participants. In individual models, slopes of all biomarkers were associated with change in MMSE and mPACC in the whole cohort. In the Aβ+ group, all biomarkers except NTA‐tau demonstrated significant associations with longitudinal MMSE and mPACC.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bali, D., Janelidze, S., Salvadó, G., Ashton, N. J., Palmqvist, S., Rodriguez, J. L., et al. (2025). Can longitudinal measures of plasma biomarkers track disease progression in early Alzheimer´s Disease? Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105473

Vancouver

Bali D, Janelidze S, Salvadó G, Ashton NJ, Palmqvist S, Rodriguez JL, et al. Can longitudinal measures of plasma biomarkers track disease progression in early Alzheimer´s Disease? Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105473.

BibTeX

@article{bali2025-5bc7b467,
  author  = {Bali, Divya and Janelidze, Shorena and Salvadó, Gemma and Ashton, Nicholas James and Palmqvist, Sebastian and Rodriguez, Juan Lantero and Stomrud, Erik and Mattsson, Niklas and others},
  title   = {{Can longitudinal measures of plasma biomarkers track disease progression in early Alzheimer´s Disease?}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_105473},
  url     = {https://doi.org/10.1002/alz70856_105473}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Abstract Background Blood based biomarkers of Alzheimer´s disease (AD) that exhibit a high degree of change over time and are associated with deterioration in cognitive performance and atrophy could be useful in clinical trials to monitor treatment responses.
Result In the whole cohort, p ‐tau217, NfL, GFAP and p ‐tau181 were significantly increased over time showing more accelerated increase in Aβ+ than Aβ‐ participants.
In individual models, slopes of all biomarkers were associated with change in MMSE and mPACC in the whole cohort.
In the Aβ+ group, all biomarkers except NTA‐tau demonstrated significant associations with longitudinal MMSE and mPACC.

Why it matters

In this longitudinal study, several plasma biomarkers rose over time and their rates of change tracked cognitive decline, especially in amyloid-positive participants. This supports using these markers to monitor disease progression in trials, but it does not show that any treatment changes these markers or outcomes.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designlongitudinal study
Participants718
Evidence strengthModerate

How this study scored 54/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	718 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.0 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record	1 / 3	Lund University: institution h-index 1,119 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 6 institution(s) in 3 countries
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Total	54 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers

Also tagged “cerebrospinal”

821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →